Published in J Clin Oncol on May 26, 2009
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
Cancer inflammation and regulatory T cells. Int J Cancer (2010) 1.40
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol (2011) 1.09
The tumor microenvironment: a pitch for multiple players. Front Oncol (2013) 1.07
Gut microbiota and the paradox of cancer immunotherapy. Front Immunol (2014) 0.95
The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med (2016) 0.93
The role of regulatory T cells in cancer. Immune Netw (2009) 0.93
Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice. Transl Oncol (2014) 0.82
The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. Appl Immunohistochem Mol Morphol (2010) 0.81
Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander? Am J Blood Res (2013) 0.80
Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med (2017) 0.75
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30
Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res (2006) 2.56
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16
Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med (2013) 2.15
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res (2012) 1.67
IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res (2011) 1.59
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51
Gene polymorphisms and cytokine plasma levels as predictive factors of complications after cardiopulmonary bypass. J Thorac Cardiovasc Surg (2012) 1.47
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol (2008) 1.47
Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure. Ann Otol Rhinol Laryngol (2002) 1.46
[Cancer immunotherapy: recent breakthroughs and perspectives]. Med Sci (Paris) (2011) 1.42
A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother (2010) 1.40
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol (2011) 1.32
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J Immunol Methods (2003) 1.29
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med (2003) 1.27
Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection. J Virol (2005) 1.26
The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol (2008) 1.25
Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology (2013) 1.21
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2012) 1.19
Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res (2008) 1.18
Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer (2004) 1.17
Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res (2012) 1.16
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother (2010) 1.08
Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood (2002) 1.05
Post-intubation laryngeal injuries and extubation failure: a fiberoptic endoscopic study. Intensive Care Med (2010) 1.04
Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol (2012) 1.01
Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck (2010) 1.00
The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol (2006) 0.97
Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance. J Immunol (2011) 0.97
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother (2008) 0.96
The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res (2008) 0.96
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res (2012) 0.96
B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol (2007) 0.95
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95
[Unilateral laryngeal paralyses: epidemiological data and therapeutic progress]. Presse Med (2003) 0.95
Transoral robotic surgery for head and neck carcinomas. Eur Arch Otorhinolaryngol (2011) 0.94
Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. Anticancer Res (2004) 0.93
The ADAMDEC1 (decysin) gene structure: evolution by duplication in a metalloprotease gene cluster on chromosome 8p12. Immunogenetics (2002) 0.93
Linker for activation of T cells integrates positive and negative signaling in mast cells. J Immunol (2004) 0.93
Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region: II. An analysis of the incidence, related variables, and consequences of local recurrence. Arch Otolaryngol Head Neck Surg (2005) 0.93
Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation. J Leukoc Biol (2007) 0.92
Endoscopic laser medial arytenoidectomy for treatment of bilateral vocal fold paralysis. Eur Arch Otorhinolaryngol (2013) 0.91
Treatment of early-stage glottic cancer by transoral laser resection. Ann Otol Rhinol Laryngol (2007) 0.90
Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res (2004) 0.90
HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers. Cancer Immun (2010) 0.90
Local control after supracricoid partial laryngectomy for "advanced" endolaryngeal squamous cell carcinoma classified as T3. Arch Otolaryngol Head Neck Surg (2004) 0.90
Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J Immunol (2008) 0.89
The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol (2003) 0.89
1st class ticket to class I: protein toxins as pathfinders for antigen presentation. Traffic (2002) 0.89
Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood (2010) 0.89
Two distinct tyrosine-based motifs enable the inhibitory receptor FcgammaRIIB to cooperatively recruit the inositol phosphatases SHIP1/2 and the adapters Grb2/Grap. J Biol Chem (2004) 0.88
CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol (2004) 0.88
Vocal tract area function for vowels using three-dimensional magnetic resonance imaging. A preliminary study. J Voice (2006) 0.87
Intracordal injection of autologous fat in patients with unilateral laryngeal nerve paralysis: long-term results from the patient's perspective. Laryngoscope (2003) 0.87
LPS induces rapid IL-10 release by M-CSF-conditioned tolerogenic dendritic cell precursors. J Leukoc Biol (2007) 0.87
Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res (2012) 0.87
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother (2011) 0.87
The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J Immunol (2010) 0.87
Characterization of immune functions in TRAF4-deficient mice. Immunology (2008) 0.87
Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. Int J Cancer (2008) 0.86
Thyroplasty type I with Montgomery implant among native French language speakers with unilateral laryngeal nerve paralysis. Laryngoscope (2005) 0.85
Dynamic interactions of Fc gamma receptor IIB with filamin-bound SHIP1 amplify filamentous actin-dependent negative regulation of Fc epsilon receptor I signaling. J Immunol (2005) 0.85
[PD-1 and PDL-1 expression in cancer: significance and prognostic value]. Med Sci (Paris) (2013) 0.84